Skip to content
OpenCapital
Get started

Replimune Group REPL Cash ratio

Cash ratio at other companies

Amgen logo
AmgenAMGN
0×0.0×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
0.6×-0.3×
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
6.1×+1.1×
Immunome logo
ImmunomeIMNM
21.3×+12.9×
CG Oncology logo
CG OncologyCGON
1×-0.9×
Erasca, Inc. logo
Erasca, Inc.ERAS
1.8×-1.0×

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+30.2%
Enterprise value$885.15M+30.0%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Calculated from Replimune Group’s reported figures.

cash and equivalents/total current liabilities=2.5×

Based on the most recent quarter.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's cash ratio?
Replimune Group (REPL) reported cash ratio of 2.5× in Q4 2025.
How has Replimune Group's cash ratio changed year-over-year?
Replimune Group's cash ratio decreased by 31.5% year-over-year, from 3.6× to 2.5×.
What is the long-term trend for Replimune Group's cash ratio?
Over 4 years (2021 to 2025), Replimune Group's cash ratio has grown at a -38.5% compound annual growth rate (CAGR), from 12.7× to 1.8×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.